Athenex, Inc.

Athenex, Inc.

ATNX

ATNXAthenex, Inc. US flag

NASDAQ Global Select

0.20

USD

- -

- -

2.33MMarket Cap

Athenex, Inc.

ATNX

(NASDAQ Global Select)

Recent

price

0.20

P/E

ratio

- -

div

yld

- -

ROIC.AI

No data availableFinancial data will appear here once available

Capital Structure

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Revenue

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

No data availableFinancial data will appear here once available

Similar Companies: Alkem Laboratories Limited (ALKEM.NS)
AstraZeneca Pharma India Limited (ASTRAZEN.NS)
Medico Remedies Limited (MEDICO.BO)
ODI Pharma AB (ODI.ST)
Orchid Pharma Limited (ORCHIDPHAR.BO)
Tianjin Ringpu Bio-Technology Co.,Ltd. (300119.SZ)
Business: Athenex, Inc. Athenex, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for cancer treatment; it operates through the Oncology Innovation Platform, which advances drug candidates including Orascovery technology such as oral paclitaxel and encequidar for metastatic breast cancer, Src kinase inhibitors like tirbanibulin ointment for actinic keratosis, skin cancers, and psoriasis, and cell therapy programs featuring KUR-501 (autologous NKT cells for relapsed-refractory high-risk neuroblastoma), KUR-502 (allogeneic for CD19-positive malignancies), and KUR-503 (for hepatocellular carcinoma); and the Commercial Platform, which handles sales and marketing of specialty pharmaceuticals. The company maintains manufacturing and supply chain operations across North America and China, targeting oncology patients and healthcare providers globally with products derived from P-glycoprotein pump inhibitors, T-cell receptor-engineered therapies, and arginine deprivation technology. Founded in 2003 and headquartered in Buffalo, New York, Athenex formerly operated as Kinex Pharmaceuticals LLC until renaming in 2015. In May 2023, Athenex filed for voluntary Chapter 11 bankruptcy proceedings in the U.S. Bankruptcy Court for the Southern District of Texas to facilitate an expedited asset sale process across its pharmaceutical division, Orascovery, and cell therapy assets, with the plan approved for liquidation by September 2023; this followed regulatory setbacks including a complete response letter for oral paclitaxel, debt reduction efforts totaling $108 million, and strategic refocusing on NKT cell therapies amid challenging market conditions. Post-bankruptcy, the company engages in winding down operations, claim resolutions, and limited ongoing activities such as fulfilling prior customer orders through its pharma solutions arm, while its stock trades over-the-counter as ATNXQ.

Company News